Grifols, S.A. American Depositary Receipt (GRFS)
Grifols: Operational Recovery And Balance Sheet Improvement Support A Return To Buy (Rating Upgrade)
First-quarter results were broadly in line with expectations, supported by strong growth in the Biopharma division, particularly immunoglobulins, where products such as Gamunex and Yimmugo continue to outperform. Grifols successfully refinanced all 2027 debt maturities ahead of schedule, extending maturities, lowering funding costs, and reducing refinancing risk. Lower plasma collection costs (with the Egyptian plasma platform), optimization of the U.S. collection network, and continued Biotest integration are expected to support sustainable margin expansion.
Grifols: Plasma Self-Sufficiency Is The Mispriced Catalyst
Grifols is transitioning from a leveraged recovery story to a strategic plasma infrastructure leader with global scale and supply security advantages. GRFS trades at a significant valuation discount—forward P/E of 8.42x and price/cash flow of 4.76x—despite robust EBITDA, margin expansion, and improving free cash flow. Recent refinancing pushes major debt maturities to 2028; management guides for 2026 EBITDA margins of at least 25% and €500–€575 million free cash flow pre-dividends.
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q1 2026 Earnings Call Transcript
Grifols: I'm Very Happy To Add In 2026
Grifols is a global leader in blood plasma, now rated 'BUY' with a €20/share PT and $23/share ADR target. GRFS has delivered €450M in cost savings, 150%+ net profit growth, and FCF exceeding guidance, with leverage down to 4.2x. Despite a BB- rating, improved fundamentals, dividend reinstatement, and forecasted 20–25% annual growth support a strong risk/reward profile.
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols, S.A. (GIKLY) Q4 2025 Earnings Call Transcript
Grifols: Positive/Neutral Scenario Posits An Upside
Grifols, S.A. has executed a turnaround, with Q3 '25 results confirming improved fundamentals, reduced leverage, and restored dividend, supporting a renewed 'Buy' rating. GRFS now trades at a normalized P/E of 14-15x, but forward multiples drop below 9x, offering significant upside if growth forecasts materialize. Operational improvements include 7%+ revenue growth, double-digit EBITDA gains, positive FCF, and leverage below 4.3x, with further refinancing underway.
Grifols, S.A. (GIKLY) Q3 2025 Earnings Call Transcript
Grifols, S.A. (OTCPK:GIKLY) Q3 2025 Earnings Call November 4, 2025 12:30 PM EST Company Participants Daniel Segarra - Head of Investor Relations & Sustainability and Vice President Jose Ignacio Abia Buenache - CEO & Director Roland Wandeler - President of Biopharma Business Unit Rahul Srinivasan - Chief Financial Officer Conference Call Participants Charles Pitman - Barclays Bank PLC, Research Division Jaime Escribano - Banco Santander, S.A.
Is Grifols (GRFS) Stock Outpacing Its Medical Peers This Year?
Here is how Grifols (GRFS) and Arcutis Biotherapeutics, Inc. (ARQT) have performed compared to their sector so far this year.
GRFS vs. ZTS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?
GRFS vs. STVN: Which Stock Should Value Investors Buy Now?
Investors looking for stocks in the Medical - Drugs sector might want to consider either Grifols (GRFS) or Stevanato Group (STVN). But which of these two stocks offers value investors a better bang for their buck right now?
Is Grifols (GRFS) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Grifols: Significant Upside Likely Materializing
Grifols demonstrates strong recovery, with leverage reduced to 4.2x and dividend reinstated, supporting a renewed investment case. GRFS posted robust Q2 2025 results: 7% revenue growth, 12.5% EBITDA growth, and near-record margins, reinforcing its global plasma leadership. Valuation remains compelling, with a new price target of €23/share and a 'BUY' rating, reflecting over 100% potential upside in coming years.
